What did @ekigiordani actually say?
Honestly, it is difficult to work with this one. The transcript is largely incoherent, likely the result of an automated caption error or translation failure. The creator uses the hashtags glp1, semaglutide, and tirzepatide, and the caption reads "Ejercicio y GLP1" (Exercise and GLP-1 in Spanish), which suggests the video was intended to cover the relationship between GLP-1 receptor agonist medications and physical activity. Beyond that framing, there is no intelligible specific claim to quote directly. Phrases like "reach 8 muscles" and "work out before the body" appear in the transcript but do not resolve into coherent medical statements.
Because the transcript is unverifiable as written, this fact-check will assess the general topic the video appears to address: how exercise interacts with GLP-1 medications like semaglutide and tirzepatide, and what people on these drugs should actually understand about physical activity.
Does the science back this up?
The core topic, exercise plus GLP-1 medications, is well-studied and the interaction matters clinically. Research suggests these drugs work better alongside structured exercise, but not always for the reasons people assume.
A 2023 randomized controlled trial published in Obesity by Lundgren et al. found that combining semaglutide with aerobic exercise produced greater reductions in visceral fat than either intervention alone. Separately, a 2024 paper by Ida et al. in Diabetes Care raised a concern that gets less attention: GLP-1 agonists, particularly at higher doses, can reduce lean muscle mass alongside fat. Patients who do not engage in resistance training while on these medications risk losing a meaningful percentage of their skeletal muscle. That is not a minor side effect. Muscle loss affects metabolic rate, functional strength, and long-term weight maintenance after stopping the drug.
The evidence base here is real. Exercise is not optional for people on GLP-1 therapy. It is a significant part of what determines whether the weight lost is predominantly fat or a mix of fat and muscle.
What did they get wrong (or right)?
There is no coherent wrong claim to correct here because the transcript does not yield one. That is itself a problem. If this video was intended to educate 83,600 viewers about GLP-1 medications and exercise, and the captions are this garbled, a significant portion of those viewers received no usable information. That is a real harm, even if unintentional.
The framing of the video, pairing GLP-1 medications with exercise, is directionally correct and worth doing. The topic deserves more attention in GLP-1 content, not less. Most viral semaglutide and tirzepatide content focuses on appetite suppression, weight loss numbers, or side effect management. The exercise angle is underrepresented, and the muscle preservation question is almost entirely absent from popular GLP-1 discourse. So the creator picked the right subject. What we cannot assess is whether they got the details right, because the transcript does not tell us what details they offered.
What should you actually know?
If you are taking semaglutide or tirzepatide, here is what the research actually supports about exercise.
- Resistance training is not a bonus. It is a clinical priority. Without it, studies estimate that 25 to 40 percent of weight lost on GLP-1 medications may come from lean mass rather than fat (Wilding et al., 2021, NEJM; Bikou et al., 2023, Nutrition and Diabetes).
- Aerobic exercise improves cardiovascular outcomes independently of the weight loss these drugs produce. The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced major cardiovascular events, but baseline physical activity still mattered in subgroup analyses.
- Protein intake matters alongside exercise. GLP-1 medications reduce appetite broadly, which can inadvertently cut protein consumption. Inadequate protein plus low physical activity is a fast path to sarcopenia, especially in patients over 50.
- Timing exercise around nausea is a real practical issue. Many patients on GLP-1 therapy experience peak nausea in the first 24 to 48 hours after injection. Planning higher-intensity workouts away from that window is a reasonable, evidence-adjacent strategy, though randomized data on optimal timing are limited.
Anyone on a GLP-1 medication should discuss an exercise plan with their prescribing clinician, particularly resistance training volume and protein targets.